Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Allegheny Health Network Researchers Receive Federal Grant to Explore Potential of Drug for Type 2 Diabetes
  • USA - English


News provided by

Allegheny Health Network

Dec 15, 2015, 07:00 ET

Share this article

Share toX

Share this article

Share toX


Pittsburgh, PA (PRWEB) December 15, 2015 -- Could a drug initially developed to treat chronic obstructive pulmonary disease (COPD) be useful in treating type 2 diabetes? Allegheny Health Network’s Institute of Cellular Therapeutics has received a $2.2 million grant from the National Institutes of Health’s (NIH) National Center for Advancing Translational Sciences (NCATS) to explore that possibility.

If we can improve insulin sensitivity and insulin production at the same time, it could substantially improve the treatment of type 2 diabetes – and, possibly, prevent the onset of clinical complications.

Post this

AHN will use the grant, distributed as part of the NCATS’s New Therapeutic Uses program, to fund a two-year clinical trial in 42 type 2 diabetics who are overweight and have problems controlling their blood sugar. The goal of the trial is to see if this new drug – used in combination with currently approved medications for type 2 diabetes – will help the body create more insulin and improve insulin sensitivity while also suppressing inflammation. Almost all overweight type 2 patients have poor insulin sensitivity. Even though their body can make insulin, a hormone that causes blood sugar to be taken up and used by mainly muscle and the liver, these patients respond poorly to the hormone’s actions. Despite significant advances in drugs that make the body produce more insulin, improved sensitivity has remained rather elusive. Emerging data demonstrate that an underlying chronic inflammation characteristic of overweight people who become diabetic is largely responsible for making the body insensitive to the actions of insulin.

“The problem is that we need to get to a point where the body can control insulin sensitivity naturally,” said Nick Giannoukakis, PhD, who wrote the grant application and will serve as AHN’s lead researcher on the trial. “To do that, we have to break the back of the inflammation.”

The drug being studied by Dr. Giannoukakis and his team was designed by AstraZeneca to short circuit inflammation. In experimental animal studies, when researchers interfered with inflammation at precisely the pressure point on which the drug acts, it not only prevented type 2 diabetes but also significantly improved insulin sensitivity as well as insulin production.

“This suggests there could be a similar effect in diabetic humans,” added Dr. Giannoukakis. “If we can improve insulin sensitivity and insulin production at the same time, it could substantially improve the treatment of type 2 diabetes – and, possibly, prevent the onset of clinical complications.”

Launched three years ago, the NCATS’s New Therapeutic Uses program strengthens the research pipeline by using an innovative strategy to identify new uses for drugs that have undergone significant research and development by the drug industry, including safety testing in humans.

“When companies like AstraZeneca provide access to drugs that already have cleared key development hurdles, it allows researchers to explore new uses for those drugs on a faster track,” said Christine Colvis, Director of the NCATS’s New Therapeutic Uses program. “This increases the odds of getting a new treatment to patients more quickly.”

The drug had a favorable safety profile when AstraZeneca initially tested it several years ago. As AHN’s randomized, double-blinded trial will be a placebo-controlled crossover study, all participants will receive the actual drug at some point during the study. AHN researchers hope to have the results by the end of 2017.

While the study will be focused on improving insulin sensitivity for type 2 diabetics, it is also possible the drug could eventually be shown to be effective in treating a variety of autoimmune diseases such as lupus, rheumatoid arthritis, juvenile diabetes and Chrohn’s disease.

“During the trial with type 2 diabetes patients, we’ll also be gathering information on the drug’s effect on specific white blood cells,” explained Dr. Giannoukakis. “This information can help us determine the drug’s potential for preventing and treating autoimmunity.”

A new and better treatment for type 2 diabetes would also have a significant impact on the enormous cost of treating the disease, Dr. Giannoukakis said. About one in five healthcare dollars in the U.S. is spent on the treatment of diabetes and its complications. Developing novel therapies to treat diseases is also a costly, complex and time-consuming process, with a 14-year average length of time from target discovery to approval of a new drug at a cost of upwards of $2 billion. The failure rate during the drug development process is more than 95 percent.

“But, just as numerous inventions for things we use every day were actually accidental discoveries, we hope to have a similar experience with this trial in the repurposing of an existing drug that was deemed safe but not effective for its original intention,” said Massimo Trucco, MD, Director of AHN’s Institute of Cellular Therapeutics.

The other physicians participating in leading the clinical arm of the trial are Patricia Bononi, MD, and Jennifer Holst, MD, of AHN, as well as Fred Toledo, MD, and Mary Korytkowski, MD, of the University of Pittsburgh School of Medicine.

For more information about AHN’s type 2 diabetes clinical study, please contact the trial team at ahnict(at)ahn.org or call 412-578-5681. To view a short video highlighting the concept of the trial at the NIH’s NCATS website, visit https://ncats.nih.gov/ntu/projects/2015#diabetes.

###

About Allegheny Health Network
Allegheny Health Network, part of Highmark Health, is an integrated healthcare delivery system serving the Western Pennsylvania region. The Network composes eight hospitals, including its flagship academic medical center Allegheny General Hospital, Allegheny Valley Hospital, Canonsburg Hospital, Forbes Hospital, Jefferson Hospital, Saint Vincent Hospital, Westfield Memorial Hospital and West Penn Hospital; a research institute; Health + Wellness Pavilions; an employed physician organization, home and community based health services and a group purchasing organization. The Network employs approximately 17,500 people and has more than 2,100 physicians on its medical staff. The Network also serves as a clinical campus for Temple University School of Medicine, Drexel University College of Medicine and the Lake Erie College of Osteopathic Medicine.

Doug Braunsdorf, Allegheny Health Network, +1 412-522-7112, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.